Proactive Investors - Run By Investors For Investors

Assertio beats 3Q estimates on broader commercial portfolio

The company advanced the development of its infantile spasm drug, cosyntropin depot
The specialty pharmaceutical recently settled a patent dispute against Purdue Pharma LP involving the pain drug OxyContin (oxycodone).

Specialty pharmaceutical company Assertio Therapeutics Inc (NASDAQ:ASRT) trounced Wall Street’s third-quarter profit and revenue estimates as it worked on broadening its commercial portfolio.

For the three months ended September 30, the Lake Forest, Illinois, company posted net income of $48.3 million and adjusted earnings per share of $0.42 on revenue of $81.2 million. The results surpassed the consensus estimates that called for Assertio to earn $0.26 on revenue of $73.7 million.

In the quarter, Assertio focused on diversifying its commercial portfolio and advancing the development of its drug cosyntropin depot, which treats infantile spasms. It plans to file for FDA approval for the drug before the close of the year.

The company also strengthened its collaboration with Collegium Pharmaceutical in the quarter regarding its Nucynta franchise, which provides additional financial incentives.

Sales for its drug Cambia jumped from last year to $10.36 million while sales for Gralise were down over the same period to $14.63 million.

READ: Assertio Therapeutics Inc shares slump after settlement of case against Purdue Pharma

The company also raised its full-year net income to be within the range of $40 million to $50 million, compared to its previous forecast of a loss of $8 million to $18 million.

“Our third-quarter performance positions us well to achieve our neurology franchise net sales and adjusted EBITDA goals for the full year,” said Arthur Higgins, Assertio’s CEO in a statement.

Last August, the specialty pharmaceutical settled a patent dispute against Purdue Pharma LP involving the pain drug OxyContin (oxycodone).

The lawsuit, which was filed in a New Jersey district court, alleged infringement by Purdue of some of Assertio’s patents with regard to Purdue’s commercialization of Oxycontin.

Under the terms of the settlement agreement, Purdue paid Assertio, which was formerly known as Depomed, US$62 million in cash. 

Assertio Therapeutics, which is headquartered in Lake Forest, Illinois, focuses on neurology and pain medicines as well as drugs to treat central nervous system conditions.

Assertio shares fell 6.3% after-hours to $4.75, having closed 0.59% lower at $5.07 Thursday.


View full ASRT profile View Profile

Assertio Therapeutics Inc Timeline

Related Articles

computing symbols in cyberspace
January 15 2019
Its team of computer scientists designs algorithms that will be used by high-frequency traders, scientists doing genetic research and pharmaceutical companies
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use